FIP1L1–PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement

Interstitial deletion involving chromosome 4q12 generates the novel tyrosine kinase fusion protein encoded by FIP1L1–PDGFRA, which is present in many patients previously labelled as having hypereosinophilic syndrome, initially reported in 2003. Reports in recent literature document excellent clinical and molecular response to the tyrosine kinase inhibitor imatinib (Glivec). This report describes the case of a 58-year-old lady, diagnosed with FIP1L1–PDGFRA positive hypereosinophilic disorder, who subsequently developed symptoms related to an intracranial lesion. Biopsy and molecular genetic studies confirmed a diffuse infiltrative lesion, with evidence of FIP1L1–PDGFRA gene fusion. Initiation of imatinib treatment led to impressive clinical and radiological response.

[1]  M. Rondoni,et al.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.

[2]  R. Sakuta,et al.  Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis , 2007, Brain and Development.

[3]  D. Gilliland,et al.  Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. , 2006, Best practice & research. Clinical haematology.

[4]  A. Tefferi,et al.  Eosinophilia: secondary, clonal and idiopathic , 2006, British journal of haematology.

[5]  A. Tefferi,et al.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. , 2004, Blood.

[6]  D. Gary Gilliland,et al.  The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management , 2004 .

[7]  E. Märker-Hermann,et al.  Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib , 2004, Annals of Hematology.

[8]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates , 2004, Clinical Cancer Research.

[9]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[10]  S. Kwon,et al.  Sequential magnetic resonance imaging findings in hypereosinophilia-induced encephalopathy , 2001, Journal of Neurology.

[11]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[12]  H. Liaño,et al.  Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. , 1986, Annals of internal medicine.

[13]  S. Schrier,et al.  The FIP 1 L 1-PDGFR fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis , classification , and management , 2004 .

[14]  M. Baccarani,et al.  Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. , 2004, Haematologica.